You just read:

Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta

News provided by

Maxwell Biotech Venture Fund

Apr 04, 2017, 09:00 ET